We appreciate the recent Perspective from Nicholson and Formea (1 ) because it allows us to clarify the role of Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for clinicians. CPIC publishes genotype-based drug therapy guidelines to help clinicians understand how genetic test results could be used to optimize drug therapy. The underlying assumption for CPIC guidelines is that clinical high-throughput and preemptive genotyping will become common practice and clinicians will increasingly have patients' genotypes, such as a cytochrome P450, family 2, subfamily D, polypeptide 6 (CYP2D6) genotype test result, available before a prescription is written (2, 3 ) . Therefore, CPIC guidelines provide guidance on how to interpret available genetic test results to improve drug therapy. For example, patients carrying 2 nonfunctional alleles that give rise to CYP2D6 poor metabolizer status derive little or no pain relief from codeine and tramadol. Thus the CPIC guideline recommends avoiding their use in these patients due to lack of efficacy and to use alternative pain medications. The guideline discusses that although alternatives might include hydrocodone or oxycodone, both have limitations. The guideline states that "there is insufficient evidence to conclude whether poor metabolizers can be expected to have decreased analgesia or whether ultrarapid metabolizers have an increased risk of toxicity with normal doses of hydrocodone," and that "it is difficult to conclude whether CYP2D6 metabolizer phenotype affects oxycodone analgesia or risk of toxicity" (4 ) . However, we acknowledge that a quick read of Table 2 of the guidelines, rather than the text, might be taken as strong advice against the use of hydrocodone and oxycodone in patients with high-risk CYP2D6 genotypes. Nonetheless, for the reasons stated in the text, and with the evidence provided in the supplement, we think it wise to alert prescribers to possible problems with hydrocodone and oxycodone in poor and ultrarapid metabolizers of CYP2D6.
Nicholson and Formea comment that "many healthcare providers follow a WHO ladder 'type' approach for the treatment of pain." They express valid concern that the entire second step includes opioids "commonly used for moderate pain (e.g., tramadol, codeine, hydrocodone, and possibly oxycodone)" that overlap with medicines that the CPIC guideline recommends avoiding (codeine and tramadol) or for which concerns are noted (oxycodone and hydrocodone). We agree with Nicholson and Formea that this creates a problem for prescribers, in that the third step includes opioids "usually reserved for severe pain presentation (e.g., morphine, oxymorphone, fentanyl, methadone, and hydromorphone)" and may be less familiar to practitioners.
However, the fact that these step 3 agents may be more difficult to use and prescribe does not negate the fact that they are alternatives to codeine and tramadol, and are not subject to concerns about CYP2D6 genotype. Although we agree with Nicholson and Formea that for "moderate pain where an opioid might be required (e.g., musculoskeletal pain, toothache), it is unlikely that the provided alternatives would be an appropriate opioid choice for routine use," the CPIC guideline is recommending these alternatives for the minority of the population with a pharmacogenetic profile that poses them at risk of therapeutic failure or adverse effects. It is exactly these patients who may require step 3 analgesics. The fact that prescribing these agents is more difficult should not deter physicians from choosing more appropriate treatment to achieve pain relief in patients with at-risk CYP2D6 genotypes.
Finally, Nicholson and Formea suggest that CPIC guideline recommendations for analgesic alternatives may be readily accepted without consideration of the complex interplay between clinical care and the proper application of pharmacogenomics. The guideline includes the caveat that "like all diagnostic tests, that for CYP2D6 genotype is one of multiple pieces of information that clinicians should consider in guiding their therapeutic choice for each patient" (4 ). The CYP2D6 and codeine guideline, like all published CPIC guidelines, includes the statement that "Guidelines are limited in scope and are not applicable to interventions or diseases not specifically identified. Guidelines do not account for all individual variations among patients and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient" (4 ) .
We thank Nicholson and Formea for their valuable feedback about the applicability of the CPIC guideline for CYP2D6 and codeine. When choosing analgesic therapy, healthcare providers must keep the whole patient in mind. We conclude that the goal of this CPIC guideline is to allow pharmacogenetic test results to serve as a tool to individualize analgesic prescribing for acute or chronic pain and thereby enable the clini-cian to make more rational treatment decisions. 
Standardizing the D-dimer Assay: Proposing the D-dimer International Managed Ratio

To the Editor:
The D-dimer assay currently lacks standardization, since each manufacturer uses a different cutoff to define an abnormal value. The existence of at least 6 commonly used assays-all with differing units and cutoffs-leads to confusion among practitioners. For instance, at our hospital, the point-of-care laboratory uses an assay with an abnormal cutoff of 230 ng/mL, but the central laboratory uses a D-dimer assay with a cutoff of 400 ng/mL. A second emergency department staffed by the same physicians uses a cutoff of 0.5 mg/L. Further, some laboratories report fibrinogen-equivalent units instead of D-dimers, resulting in a value approximately twice that of the D-dimer.
Recent literature has demonstrated that the "standard" threshold of 500 ng/mL may be adjusted depending on patient-specific factors, enhancing the D-dimer's diagnostic specificity in evaluation of suspected venous thromboembolism in older or pregnant patients (1, 2 ) . Variable cutoffs hamper the implementation of these adjustments, confusing practitioners when local assays do not correspond to internationally published values. In our experience, this frustrates practitioners and increases their motivation to skip D-dimer testing and proceed directly to pulmonary vascular imaging, or worse, commit frank medical error by failing to recognize a positive test result (3 ).
We sent an open Research Electronic Data Capture (REDCap) 1 survey to clinicians in the US to determine physician opinions surrounding the use, adjustment, and normalization of D-dimer testing. The survey used a visual analog scale (VAS) and multiple-choice questions designed to assess the magnitude of the problem and the desire for a solution. Clinicians additionally could submit their electronic signature on a petition to the FDA, requesting that the FDA take steps to normalize the D-dimer threshold.
Statistical analysis was performed using SPSS (IBM Corp., Armonk NY). Descriptive statistics are presented for appropriate variables. Median responses are reported with interquartile ranges (IQRs) for nonnormal data. A total of 1006 physicians responded, representing approximately 3.1% of all emergency
